- Must have met the inclusion criteria for preceding double-blind study
- Have received double-blind study medication and wish to receive open-label
- Cannot be pregnant or considering becoming pregnant during the course of the study.
- Cannot be receiving any concomitant medication that could alter the effectiveness of
the pregabalin response or affect seizure frequency.